• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patient enrollment strong predictor of phase II oncology trials total costs

Patient enrollment strong predictor of phase II oncology trials total costs

October 4, 2013
CenterWatch Staff

Phase II trials almost always see an increase in patient enrollment over phase I trials, according to a recent Cutting Edge Information study.

Oncology Clinical Trials: Drug Development Resources and Case Studies discovered that while not nearly as large as phase III enrollment, phase II trials often require more than 100 patients—and sometimes many more—to complete.

Surveyed pharmaceutical companies revealed phase II trials’ actual enrollments average 121 patients. “Not surprisingly, the actual number of patients enrolled does not equate to the number of planned enrollments,” said Ryan McGuire, research team leader at Cutting Edge Information. “Patient recruitment has always been, and may always be, a key struggle for clinical teams.”

The planned and actual enrollment levels studied range from limited (10 patients) to large (300 patients) for phase II trials. Interestingly, only 43% of pharma companies that provided data hit their goals—demonstrating the difficulties associated with patient enrollment. The data show a relationship between enrollment and costs. Costs steadily increase as the number of patients needed rises (with only a few exceptions). In fact, the correlation coefficient of .86 indicates that patient enrollment is a very strong predictor of phase II total trial costs.

Further breakdown of this data show phase II trials with 100 or fewer patients cost an average of $4.9 million. Trials with 101 to 199 patients cost an average of $7 million. Finally, the cost of trials with more than 200 patients increases tremendously, to an average of $25.7 million.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing